evaluate the digital health company amwell on ozempic / semaglutide Could This Be New Ozempic? Sweetening the deal: an infodemiological
Description
Supports gut microbiome balance
Explore the findings here:
The STELLUX®
Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials
